Stockreport

Achillion Initiates Phase I First-In Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D

ACHISON INC A  (ACHN) 
Last achison inc a earnings: 11/7 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.achillion.com/investor-relations
PDF NEW HAVEN, Conn., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a pharmaceutical company focused on advancing small molecule inhibit [Read more]